Mazen Darwazah - Hikma Pharmaceuticals Chairman
| HKMPF Stock | USD 24.47 1.91 8.47% |
Chairman
Mr. Mazen Samih Talib Darwazah is Executive Vice Chairman of the Board, President and Chief Executive Officer of MENA and Emerging Markets of Hikma Pharmaceuticals Plc. Mazen has led and expanded the MENA region at Hikma. Since listing, he has Group level responsibility in his role as Executive Vice Chairman. Since 2014, he became responsible for the Groups expansion into emerging markets. BA in Business Administration from the Lebanese American University, AMP from INSEAD. since 2014.
| Age | 65 |
| Tenure | 10 years |
| Phone | 44 20 7399 2760 |
| Web | https://www.hikma.com |
Hikma Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.077 % which means that it generated a profit of $0.077 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.154 %, meaning that it generated $0.154 on every $100 dollars invested by stockholders. Hikma Pharmaceuticals' management efficiency ratios could be used to measure how well Hikma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 7 records | CHAIRMAN Age | ||
| Mark Garrett | Axalta Coating Systems | 57 | |
| William Cook | Axalta Coating Systems | 67 | |
| David Lamp | CVR Partners LP | 66 | |
| Mark Pytosh | CVR Partners LP | 59 | |
| Wing Ho | Emerson Radio | 68 | |
| Mark Costa | Eastman Chemical | 58 | |
| WingOn Ho | Emerson Radio | 73 | |
Management Performance
| Return On Equity | 0.15 | |||
| Return On Asset | 0.077 |
Hikma Pharmaceuticals PLC Leadership Team
Elected by the shareholders, the Hikma Pharmaceuticals' board of directors comprises two types of representatives: Hikma Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hikma. The board's role is to monitor Hikma Pharmaceuticals' management team and ensure that shareholders' interests are well served. Hikma Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hikma Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Riad Mishlawi, EU Vice President and Global Head - Injectables | ||
| Engineer Darwazah, Ex CEO | ||
| Mazen Darwazah, Executive Vice Chairman, Member of Compliance, Responsibility and Ethics Committee, Member of Nomination Committee, CEO of MENA and Emerging Markets and President of MENA and Emerging Markets | ||
| Khalid Nabilsi, Chief Officer | ||
| CPA CFA, Exec MA | ||
| Brian Hoffmann, Pres Generics | ||
| Hussein Arkhagha, General Counsel | ||
| Samuel Park, Global US | ||
| Susan Ringdal, Vice President - Corporate Strategy and Investor Relations | ||
| Majda Labadi, Corporate Vice President - Human Resources |
Hikma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hikma Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | |||
| Return On Asset | 0.077 | |||
| Profit Margin | 0.14 % | |||
| Operating Margin | 0.22 % | |||
| Current Valuation | 5.26 B | |||
| Shares Outstanding | 220.26 M | |||
| Shares Owned By Insiders | 29.67 % | |||
| Shares Owned By Institutions | 41.69 % | |||
| Price To Earning | 7.89 X | |||
| Price To Book | 1.84 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Hikma Pink Sheet
Hikma Pharmaceuticals financial ratios help investors to determine whether Hikma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hikma with respect to the benefits of owning Hikma Pharmaceuticals security.